Regional expression and activity of breast cancer resistance protein (Bcrp/Abcg2) in mouse intestine: Overlapping distribution with sulfotransferases

被引:53
|
作者
Enokizono, Junichi [1 ]
Kusuhara, Hiroyuki [1 ]
Sugiyama, Yuichi [1 ]
机构
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan
关键词
D O I
10.1124/dmd.106.011239
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Breast cancer resistance protein (Bcrp/Abcg2) is a member of the ATP-binding cassette transporter family with the ability to transport a variety of sulfate conjugates. In the present study, the regional expression and activity of Bcrp and sulfotransferases (SULTs/Sults) were investigated in mouse intestine. Western blotting analysis revealed the highest expression of Bcrp in the ileum over the duodenum, jejunum, and colon. Functional analysis of Bcrp was performed in everted intestinal sacs using 4-methylumbelliferone (4MU). The mucosal secretion clearance of 4MU sulfate formed in the enterocytes was markedly reduced in the jejunum, ileum, and colon of Bcrp (-/-) mice in comparison with wild- type mice, whereas a slight and nonsignificant reduction was observed in the duodenum. The reduction in the mucosal secretion clearance was most marked in the ileum followed by the colon and jejunum. In addition, the mucosal secretion clearance of minoxidil sulfate, an active metabolite of minoxidil, was also significantly reduced in the intestine of Bcrp (-/-) mice. The sulfation activity of 4MU was higher in the colon than in the small intestine where glucuronidation activity was somewhat higher than the sulfation activity. Real-time polymerase chain reaction analysis showed that the expression of sulfotransferases, such as Sult1a1/2, Sult1b1, and Sult1d1, was also highest in the colon. These results suggest that Bcrp activity is higher in the mid to lower intestine and that the cooperation of Bcrp and SULT provides an important detoxification pathway, particularly in the colon.
引用
收藏
页码:922 / 928
页数:7
相关论文
共 50 条
  • [1] COOPERATIVE DETOXIFICATION OF XENOBIOTIC COMPOUNDS BY BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) AND SULFOTRANSFERASES
    Enokizono, Junichi
    Kusuhara, Hiroyuki
    Sugiyama, Yuichi
    DRUG METABOLISM REVIEWS, 2007, 39 : 22 - 22
  • [2] Breast cancer resistance protein (BCRP/ABCG2)
    Staud, F
    Pavek, P
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2005, 37 (04): : 720 - 725
  • [3] Expression and functional characterization of breast cancer resistance protein (ABCG2) in mouse intestine
    Enokizono, J
    Kusuhara, H
    Sugiyama, Y
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2005, 125 : 138 - 139
  • [4] Targeting breast cancer resistance protein (BCRP/ABCG2) in cancer
    Chen, Rouan
    Yu, Yue
    Liu, Ruixin
    Chen, Qian
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (11) : 6550 - 6564
  • [5] Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy
    Hahnova-Cygalova, Lenka
    Ceckova, Martina
    Staud, Frantisek
    DRUG METABOLISM REVIEWS, 2011, 43 (01) : 53 - 68
  • [6] Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy
    Noguchi, Kohji
    Katayama, Kazuhiro
    Mitsuhashi, Junko
    Sugimoto, Yoshikazu
    ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (01) : 26 - 33
  • [7] Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
    L Austin Doyle
    Douglas D Ross
    Oncogene, 2003, 22 : 7340 - 7358
  • [8] Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
    Doyle, LA
    Ross, DD
    ONCOGENE, 2003, 22 (47) : 7340 - 7358
  • [9] Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract
    Gutmann, H
    Hruz, P
    Zimmermann, C
    Beglinger, C
    Drewe, J
    BIOCHEMICAL PHARMACOLOGY, 2005, 70 (05) : 695 - 699
  • [10] Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance
    Natarajan, Karthika
    Xie, Yi
    Baer, Maria R.
    Ross, Douglas D.
    BIOCHEMICAL PHARMACOLOGY, 2012, 83 (08) : 1084 - 1103